May 2, 2012 by Brian Orelli, PhDAre Supply Troubles a Biotech Buying Opportunity?Running production close to demand trips up ViroPharma.
May 2, 2012 by Brian Orelli, PhDThis Biotech Needs to Strike FastProtalix gets its first FDA approval, but is its window of opportunity closing?
Apr 30, 2012 by Brian Orelli, PhDWhen Will Spectrum's Run End?Fusilev sales dominate, but can they last?
Apr 30, 2012 by Brian Orelli, PhDAnother Reason to Get Excited About VIVUSVIVUS gets its new erectile dysfunction drug Stendra approved.
Apr 30, 2012 by Brian Orelli, PhDMannKind Rents Out a Drug ProgramA licensing deal with a take-back option.
Apr 30, 2012 by Brian Orelli, PhDThe Big Bet on ProtalixWill the FDA approve Protalix's taligucerase on its second attempt?
Apr 30, 2012 by Brian Orelli, PhDSequenom Starts to Show ItDown syndrome test increases, but investors are still worried.
Apr 30, 2012 by Brian Orelli, PhD1 Unexcitingly Good Dividend PlayMerck has slow growth, but that's OK.
Apr 27, 2012 by Brian Orelli, PhDWill the FDA Approve VIVUS' Avanafil?Seems likely, but don't expect shares to get hot and heavy.
Apr 27, 2012 by Brian Orelli, PhDSeeing Black Gives Regeneron a 9% PopRegeneron registers its first profitable quarter.
Apr 27, 2012 by Brian Orelli, PhDCome On, Amylin, Just a Little Clue?The pharmaceutical company needs to tell its investors what its plan is.
Apr 27, 2012 by Brian Orelli, PhDMaybe There Will Be Some Hep C Patients LeftSales of Vertex's Incivek decline substantially.
Apr 26, 2012 by Brian Orelli, PhDA Little Confidence Goes a Long WayKeryx gets a boost from partner data.
Apr 26, 2012 by Brian Orelli, PhDAnemic Growth? Not From These Drugs.Amgen overcomes substantial drops in its anemia franchise.
Apr 25, 2012 by Brian Orelli, PhDWill the FDA Expand the Label for Amgen's Xgeva?Approved or not, an expansion doesn't look likely.
Apr 25, 2012 by Brian Orelli, PhDHuman Genome Lays Out Its Valuation CaseFirst-quarter earnings? What's that?
Apr 24, 2012 by Brian Orelli, PhDA Bad News Buy for Gutsy, Patient InvestorsAchillion gets knocked down but isn't out of the race.
Apr 24, 2012 by Brian Orelli, PhDWarning: Good Biotechs Get Acquired; the Rest Don'tBuy because they're good, not because they'll get acquired.
Apr 23, 2012 by Brian Orelli, PhDPfizer Drives a Hard BargainPfizer gets a good price for its nutrition business.
Apr 23, 2012 by Brian Orelli, PhDGreat Deal. Now What?Cell Therapeutics licenses a drug at an inopportune time.
